Arbor Biotechnologies (Series C)
Funding Details
Awarder
Inbox
Date Award
March 18, 2025
Vertical
Genetic Medicine
Funding URL
View Funding Page
Funding Amount
$74,000,000
Company Info
Traction
The company is advancing its lead program into clinical testing with a Phase 1/2 trial planned to enroll about two dozen volunteers.
Market
Rare Diseases
Location
USA
Coinvestors
Arch Venture Partners, TCGX
Company Description

Arbor Biotechnologies is developing gene editing therapies for rare diseases, specifically targeting primary hyperoxaluria type 1 with its lead program ABO-101, which aims to provide a one-time treatment solution.

Links
Back to HomeBack to Genetic Medicine DealsView Funding Announcement